The thyroid cancer warning on Wegovy, Zepbound and Saxenda, explained

Open the leaflet for Wegovy, Zepbound or Saxenda and the first thing you hit is a black-boxed warning about thyroid cancer. It is the strongest kind of warning the FDA issues, and it is genuinely alarming to read cold. So here is what it actually says, why it is there, and what the same labels say is still unknown.

Everything below is quoted from the FDA-approved prescribing information for each drug, read on 4 September 2026, with links in the sources. I have not added any interpretation of the risk beyond what the labels themselves state.

A boxed warning is not a statement that a drug causes harm. It is a requirement that a specific piece of information be placed where nobody can miss it. What it flags here is a finding in animals and a gap in the human evidence — and the labels are unusually explicit about the difference.

What the warning actually says

Here is the Wegovy (semaglutide) boxed warning in full, from the label revised 6/2026:

“In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of WEGOVY and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY.”

Zepbound (tirzepatide), label revised 8/2026, changes the species and the drug name and drops Wegovy’s closing line about calcitonin monitoring: “In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.”

Saxenda (liraglutide), revised 6/2026, is the same again: “Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice.”

Three drugs, two companies, one paragraph. That uniformity is itself informative — this is a class-wide warning applied to a class-wide finding, not something discovered about one product.

Why it exists: the rodent studies

C-cells are a small population of cells in the thyroid that produce calcitonin. Medullary thyroid carcinoma is the cancer that arises from them. It is rare in humans, and it is the specific tumour type the warning concerns — not the far more common thyroid cancers most people have heard of.

The finding comes from lifetime carcinogenicity studies in rodents. Wegovy’s section 5.1 describes it: “In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant plasma exposures.” Zepbound’s section 5.1 reports the same pattern from “a 2-year study at clinically relevant plasma exposures” in rats.

Two details in that wording carry weight. “Dose-dependent” and “treatment-duration-dependent” mean the effect scaled with how much and how long — the signature of a real biological effect rather than background noise. And “at clinically relevant exposures” means it happened at drug levels comparable to those people receive, not only at extreme doses. That combination is why the warning sits in a box rather than in the ordinary warnings section.

What the labels say is not known in humans

This is the part that tends to get lost. The same warning that reports the rodent finding also states, in the same breath, that the human question is open. Wegovy, Zepbound and Saxenda all use the phrase “It is unknown whether”, and all four — Foundayo included — add that the “human relevance” of the rodent tumours “has not been determined”.

On the human data that does exist, Wegovy’s section 5.1 is precise: “Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.” Foundayo’s label carries that same sentence. Saxenda’s section 5.1 makes the equivalent point about its own postmarketing reports.

“Insufficient to establish or exclude” is doing a lot of work there, and it is worth reading literally. It does not say the reports show a risk. It does not say they rule one out. It says the evidence cannot settle the question in either direction.

The labels are equally clear that screening is not the answer to that uncertainty. Wegovy’s section 5.1: “Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY. Such monitoring may increase the risk of unnecessary procedures, due to the low-test specificity for serum calcitonin and a high background incidence of thyroid disease.” In other words, testing everyone would generate more false alarms and unnecessary procedures than answers.

Who the labels say should not take these drugs

Here the labels stop hedging. All four GLP-1 drugs list the same contraindication, in identical terms — Wegovy is “contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”, and Zepbound, Saxenda and Foundayo repeat it in near-identical terms (Saxenda uses “and” where the others use “or”).

MEN 2 is an inherited condition that raises the risk of medullary thyroid carcinoma. Note the word “family”: the contraindication covers a relative’s history, not only your own. That makes it one of the few things about these drugs worth checking before a first appointment rather than during one, since it may require a phone call to a relative. The eligibility page covers the other conditions prescribers screen for.

The symptoms the labels tell patients to report

Every one of the four boxed warnings carries the same instruction to prescribers: counsel patients about the potential risk and “inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness)”.

In plain English, those four are: a lump in the neck, difficulty swallowing, shortness of breath, and a hoarse voice that does not go away. The labels do not say these symptoms mean cancer — they are the things worth mentioning to a prescriber rather than waiting out. Wegovy’s section 5.1 adds that “patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated”.

Foundayo’s warning is worded differently, and the difference matters

Foundayo (orforglipron) also carries a boxed warning headed “WARNING: RISK OF THYROID C-CELL TUMORS”. But read the text and it is not the same warning at all:

“In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents. While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined.”

So Foundayo’s own rodent studies produced no tumours — and the label says so explicitly — because the drug does not activate the rodent version of the receptor. The warning is applied on the basis of the class, not on the basis of a finding with this molecule. The contraindication and the symptom counselling that follow are identical to the other three.

The three drugs that carry no thyroid warning

The other three approved weight loss drugs are not GLP-1 drugs, and their labels contain nothing on this at all. I searched each one: Qsymia (revised 4/2026) has no boxed warning and no mention of C-cells or medullary carcinoma anywhere in its prescribing information. Contrave (revised 11/2025) has a boxed warning, but it is headed “WARNING: SUICIDAL THOUGHTS AND BEHAVIORS” and concerns the bupropion component — a completely different issue, with no thyroid content in the label. Xenical (orlistat), revised 7/2024, has no boxed warning and no C-cell language either; its thyroid mentions relate only to an interaction with levothyroxine.

If the warning is what is holding you back, the useful thing to bring to an appointment is your family thyroid history, since that is the one part of this the labels treat as settled. Our page on talking to your doctor has other questions worth raising, and the explainer on how GLP-1 drugs work covers the receptor biology this warning turns on.